

Fotis Asimakopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4836923/publications.pdf>

Version: 2024-02-01

32
papers

1,129
citations

586496

16
h-index

563245

28
g-index

35
all docs

35
docs citations

35
times ranked

2382
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of <i>Nras</i> <i>Q61R</i> and <i>MYC</i> transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. <i>Blood</i> , 2021, 137, 61-74.	0.6	21
2	Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical. <i>Leukemia and Lymphoma</i> , 2021, 62, 1518-1521.	0.6	4
3	Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S146-S147.	2.0	0
4	Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2020, 68, 871-885.	1.3	38
5	Versican in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1272, 55-72.	0.8	19
6	Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model. <i>Blood</i> , 2020, 136, 10-11.	0.6	0
7	Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2558-2562.	0.6	13
8	Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4653-4653.	0.6	1
9	Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination. <i>Blood</i> , 2019, 134, 1210-1210.	0.6	3
10	Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT). <i>Blood</i> , 2019, 134, 3088-3088.	0.6	0
11	Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF- κ B activity and increases drug resistance in multiple myeloma. <i>Journal of Biological Chemistry</i> , 2018, 293, 2452-2465.	1.6	35
12	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. <i>JAMA Oncology</i> , 2018, 4, 343.	3.4	130
13	TIGIT checkpoint inhibition for myeloma. <i>Blood</i> , 2018, 132, 1629-1630.	0.6	10
14	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
15	Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. <i>Journal of Leukocyte Biology</i> , 2017, 102, 265-275.	1.5	31
16	Mechanisms of Resistance in Multiple Myeloma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 251-288.	0.9	20
17	Versican-Derived Matrikines Regulate Batf3 Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. <i>Journal of Immunology</i> , 2017, 199, 1933-1941.	0.4	82
18	Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. <i>Blood</i> , 2016, 128, 680-685.	0.6	119

#	ARTICLE	IF	CITATIONS
19	Deploying myeloid cells against myeloma. <i>Oncolmmunology</i> , 2016, 5, e1090076.	2.1	2
20	Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies. <i>Journal of Biological Chemistry</i> , 2016, 291, 3268-3279.	1.6	75
21	Single-molecule analysis reveals widespread structural variation in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7689-7694.	3.3	43
22	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. <i>Cancer Immunology Research</i> , 2015, 3, 881-890.	1.6	24
23	LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. <i>Journal of Clinical Investigation</i> , 2015, 125, 304-315.	3.9	56
24	Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 875-882.	1.1	31
25	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. <i>Blood</i> , 2014, 123, 3305-3315.	0.6	89
26	Macrophages in multiple myeloma: emerging concepts and therapeutic implications. <i>Leukemia and Lymphoma</i> , 2013, 54, 2112-2121.	0.6	47
27	<sc>MAP</sc>3K8 kinase regulates myeloma growth by cellâ€autonomous and nonâ€autonomous mechanisms involving myelomaâ€associated monocytes/macrophages. <i>British Journal of Haematology</i> , 2013, 160, 779-784.	1.2	12
28	Recovery Of Natural Killer Cells and Monocyte Subsets Following Autologous Peripheral Blood Stem Cell Transplantation Predicts Longer Progression Free Survival Among Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 2126-2126.	0.6	3
29	Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. <i>British Journal of Haematology</i> , 2012, 158, 336-346.	1.2	100
30	Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche. <i>Blood</i> , 2012, 120, 443-443.	0.6	1
31	Optical Mapping of the Myeloma Cancer Genome to Elucidate Mechanisms of Acquired Resistance to Proteasome Inhibitors.. <i>Blood</i> , 2012, 120, 2444-2444.	0.6	0
32	Cell-Specific Transduction of <i>Prdm1</i>-Expressing Lineages Mediated by a Receptor for Avian Leukosis Virus Subgroup B. <i>Journal of Virology</i> , 2009, 83, 4835-4843.	1.5	1